Insider attacks: Purdue developing new treatment options for millions with autoimmune diseases

old age
Credit: CC0 Public Domain

Living with an autoimmune disease can feel like an insider is attacking your body. An estimated 24 million people in the United States are affected by autoimmune diseases, a group of diseases in which the person's immune system attacks part of the person's own body.

Now, Purdue University researchers have developed a series of molecules that may provide more reliable relief with fewer side effects for people with any of several autoimmune diseases. The new molecules overcome difficulties with current drugs in targeting, for purposes of inhibiting, the appropriate form of Janus kinase, which has four forms affecting cell signaling and gene expression.

The new inhibitors may provide relief for people suffering from rheumatoid arthritis, psoriasis, myelofibrosis and other autoimmune diseases with a reduction in side effects compared with current therapies. The research appears in the November edition of the Journal of Medicinal Chemistry.

"Our new molecules fit within the emerging field of therapeutically useful Janus kinase inhibitors that have attracted a lot of attention and excitement within the medicinal chemistry community and the general field of medicine," said Mark Cushman, a distinguished professor of medicinal chemistry in Purdue's College of Pharmacy, who leads the . "Our compounds contribute a new structural chemotype that is expected to have unique pharmacological properties relative to the other known Janus kinase inhibitors."

Cushman, a member of the Purdue University Center for Cancer Research, said the new also show potential to allow for more treatment options for people with autoimmune diseases. Abnormalities of the immune system often lead to or cancer.

Researchers filed a patent with the Purdue Office of Technology Commercialization and the technology is available for licensing.


Explore further

Baldness caused by alopecia could soon be treatable

More information: Mohamed S. A. Elsayed et al, Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) Series, Journal of Medicinal Chemistry (2018). DOI: 10.1021/acs.jmedchem.8b00510
Journal information: Journal of Medicinal Chemistry

Provided by Purdue University
Citation: Insider attacks: Purdue developing new treatment options for millions with autoimmune diseases (2018, December 6) retrieved 21 April 2019 from https://medicalxpress.com/news/2018-12-insider-purdue-treatment-options-millions.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more